This is a published notice on the Find a Tender service: https://www.find-tender.service.gov.uk/Notice/026822-2024

Contract

Covid-19 nMAB Infusion Service at Home

NHS Surrey Heartlands Integrated Care Board

F03: Contract award notice

Notice identifier: 2024/S 000-026822

Procurement identifier (OCID): ocds-h6vhtk-0468c4

Published 22 August 2024, 12:12pm

Section I: Contracting authority

I.1) Name and addresses

NHS Surrey Heartlands Integrated Care Board

Surrey Heartlands Block C, 1st Floor, Dukes Court, Duke Street

Woking

GU21 5BH

Email

nhscs.corporateservices@nhs.net

Telephone

+44 1306646822

Country

United Kingdom

Region code

UKJ26 - East Surrey

Internet address(es)

Main address

https://www.surreyheartlands.org/nhs-surrey-heartlands-board

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Covid-19 nMAB Infusion Service at Home

Reference number

NMAB001

II.1.2) Main CPV code

• 85141200 - Services provided by nurses

II.1.3) Type of contract

Services

II.1.4) Short description

This contract is for the provision of a nurse led homecare service to administer intravenous COVID-19 neutralising monoclonal antibodies to eligible community patients registered with a GP in Surrey Heartlands or Frimley in line with NICE TA878.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £408,000

II.2) Description

II.2.3) Place of performance

NUTS codes

• UKJ26 - East Surrey

Main site or place of performance

Homes of patients registered with a GP in:

Surrey Heartlands ICB - East Surrey, Guildford & Waverley, Surrey Downs

Frimley ICB

II.2.4) Description of the procurement

This notice is an intention to award a contract under the PSR, having followed a competitive process. The contract is for the value of £408,000 over three years.

This is a new service provider following notice having been given by a prior supplier for an existing service. During the interim period IV administration has needed to be delivered at a specialist centre in the absence of an infusion service at home.

The service will commence on 1st October 2024; the contract will expire on 30th September 2027.

This contract is for the provision of a nurse led homecare service to administer intravenous COVID-19 neutralising monoclonal antibodies to eligible community patients registered with a GP in Surrey Heartlands ICB except North West Surrey Place which has alternate provision and Frimley ICB in line with NICE TA878.

Patients will have been clinically assessed by East Berkshire Primary Care Trust (EBPCT) and where necessary prescribed IV therapy due to their individual patient circumstances.

The IV therapy is dispensed and delivered by a named community pharmacy in Surrey Heartlands or Frimley which will refer patients onto the home care IV administration service.

EBPCT is also responsible for clinically assessing patients who may be geographically located in the Surrey Heartlands and Frimley areas (except North West Surrey in Surrey Heartlands), explicitly patients in detained estate or Mental Health wards and patients who are holiday in the area.

The aim of the service is to ensure patients within the ICS' can access the provision of homecare IV fairly and equitably and that all patients referred into the service receive IV therapy with 5 days of symptom onset. Some patients may receive therapy on day 6 or 7 with the agreement of the prescribing trust.

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: No

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number: <u>2024/S 000-021381</u>

Section V. Award of contract

A contract/lot is awarded: Yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract

9 August 2024

V.2.2) Information about tenders

Number of tenders received: 3

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Ashfield Healthcare Limited

Ground Floor, Ceva House Excelsior Road, Ashby Business Park, Nottingham Road

Ashby?De?La?Zouch

LE65 1NG

Country

United Kingdom

NUTS code

• UKJ26 - East Surrey

National registration number

03286306

The contractor is an SME

No

V.2.4) Information on value of contract/lot (excluding VAT)

Total value of the contract/lot: £408,000

Section VI. Complementary information

VI.3) Additional information

This is a Provider Selection Regime (PSR) Intention to Award Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to the relevant authority by midnight on 3rd September 2024. This contract has not yet formally been awarded; this notice serves as an intention to award a contract under the competitive process of the PSR.

Written representations should be sent to syheartlandsicb.contractsadmin@nhs.net.

Award Decision makers: Evaluation Panel, Surrey Heartlands Commissioning, Contracting and Commercial Committee - Meetings in May and July 2024, Executive Director of Recovery and Sustainability

No Conflicts of Interest were declared for this competitive process.

The PSR Key Criteria were allocated in the following weightings:

Key Criteria 1: Quality & Innovation 25%

Key Criteria 2: Value 26%

Key Criteria 3: Integration, Collaboration and Service Sustainability 24%

Key Criteria 4: Improving access, reducing health inequalities, and facilitating choice 15%

Key Criteria 5: Social Value 10%

Key criteria 1-3 were of effective equal weighting due to an emphasis on the need for assurance regards service model quality, delivery, sustainability, and cost implications inherent therein. Additionally, it was important to gain confidence in a bidder's ability to mobilise the service efficiently demonstrating collaboration and team working during this time and for future service delivery. The Authority sought a most economically advantageous response. The number of technical evaluation questions posed for each Key Criteria 1-3 differed as the breadth of information altered hence the small percentage differences. Key Criteria 4 and 5 were allocated a reduced weighting because some elements of Key Criteria 4 are outside of the control of the provider due to its referral receipt status. Key criteria 5 was allocated the minimum weighting but this was still considered adequate for bidders to demonstrate their credentials in this arena with a

weighting influential enough to impact their status in the procurement process. The winning bidder achieved the highest scores in relation to Key Criteria 2, 4 and 5.

VI.4) Procedures for review

VI.4.1) Review body

Independent Patient Choice and Procurement Panel

London

Country

United Kingdom